Pharmaceutical Industry 2026

PHARMA 2026: From Scale to Innovation provides a comprehensive, data-driven analysis of the global pharmaceutical industry based on FY2025 results.

The competitive landscape of the pharmaceutical industry is changing. Scale alone no longer defines leadership. Long-term value creation increasingly depends on the ability to continuously generate innovative medicines, build strong research platforms, concentrate resources in high-growth therapeutic areas, and translate R&D investment into sustainable growth.

This full report integrates company analysis, pharmaceutical market analysis, R&D pipelines, and emerging drug technologies into a single reference, covering 30 leading global pharmaceutical companies and more than 600 major marketed and clinical-stage drugs.

Part I - Industry Themes: The Changing Competitive Landscape

Part I examines how competition among global pharmaceutical companies is shifting from scale to innovation capability.

In addition to traditional sales rankings, the report evaluates companies through original analytical frameworks including Value Creation Ratio, R&D Efficiency, Growth Classes, and Research Platforms. It analyzes financial performance, growth structure, product portfolios, and late-stage R&D pipelines to identify the factors increasingly differentiating industry leaders.

The dramatic rise of Eli Lilly illustrates this structural change. Supported by a long-established research platform in metabolic diseases, the company expanded pharmaceutical sales from approximately $45 billion to $65 billion in a single year and moved from ninth to first place in the global ranking.

Part II - New Drug R&D and Market Analysis

Part II reorganizes pharmaceutical innovation from two complementary perspectives: drug classes and therapeutic areas.

Each section combines:

• Current market structure and competitive trends

• Five-year sales trends of major products

• Mechanisms of action and therapeutic positioning

• Regulatory approvals and indication expansions

• Major clinical trial developments

• Emerging modalities and next-generation technologies

Products with the most recent developments are presented first, while established products provide the historical context needed to understand how each therapeutic market has evolved.

Together, these analyses reveal not only which products and markets are growing, but also the scientific and competitive forces driving those changes.

A 620-Page Reference for Pharmaceutical Industry Analysis

By connecting companies, products, markets, R&D pipelines, and drug discovery technologies, PHARMA 2026 provides an integrated framework for understanding the structural transformation of the pharmaceutical industry.

Designed for professionals involved in corporate strategy, investment analysis, business development, pharmaceutical research, and competitive intelligence, this 620-page report serves as a practical reference for evaluating where the industry stands today-and where the next generation of pharmaceutical growth may emerge.